Yishen Jiangzhuo decoction attenuates cisplatin‑induced acute kidney injury by inhibiting inflammation, oxidative stress and apoptosis through the TNF signal pathway

Zheng,Dengyong; Ruan,Xinglin; Wu,Qiang; Qiu,Yuliang; Ruan,Shiwei

doi:10.3892/etm.2024.12620

Yishen Jiangzhuo decoction attenuates cisplatin‑induced acute kidney injury by inhibiting inflammation, oxidative stress and apoptosis through the TNF signal pathway

Authors:
- Dengyong Zheng
- Xinglin Ruan
- Qiang Wu
- Yuliang Qiu
- Shiwei Ruan
View Affiliations

Affiliations: Academy of Integrative Medicine, Fujian University of Traditional Chinese Medicine, Fuzhou, Fujian 350122, P.R. China, Department of Neurology, Fujian Medical University Union Hospital, Fuzhou, Fujian 350001, P.R. China, Department of Nephrology, The Second Affiliated People's Hospital of Fujian University of Traditional Chinese Medicine, Fuzhou, Fujian 350003, P.R. China, Department of Nephrology, People's Hospital Affiliated to Fujian University of Traditional Chinese Medicine, Fuzhou, Fujian 350004, P.R. China
Published online on: June 20, 2024 https://doi.org/10.3892/etm.2024.12620
Article Number: 331
Copyright: © Zheng et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study aimed to investigate the therapeutic effects and mechanisms of Yishen Jiangzhuo decoction (YSJZD) in a mouse model of cisplatin‑induced acute kidney injury (AKI). The mice were divided into the NC, cisplatin and cisplatin + YSJZD groups. A concentration‑dependent effect of YSJZD on cisplatin‑induced AKI was observed and the optimal concentration for intervention was calculated. Changes in blood urea nitrogen and serum creatinine levels combined with hematoxylin and eosin and periodic acid‑Schiff staining and transmission electron microscopy observations indicated that YSJZD enhanced renal function, reduced pathological injury and protected renal tubular epithelial cells in cisplatin‑induced AKI mice. The results of the transcriptomic and enrichment analyses showed that the mechanisms of YSJZD may be associated with inflammation, oxidation, apoptosis and the TNF signal pathway. Immunofluorescence, oxidative stress index, terminal deoxynucleotidyl transferase dUTP nick end labeling assay and western blotting revealed that YSJZD downregulated apoptosis in the renal tissues of AKI mice and further decreased the expression levels of p‑p65, p‑p38 MAPK, TNF‑α, cleaved‑caspase‑3 and malondialdehyde, while increasing the levels of NAD‑dependent protein deacetylase sirtuin‑3, glutathione and superoxide dismutase. Overall, the results showed that YSJZD could effectively abrogate cisplatin‑induced AKI in mice through mechanisms primarily related to its anti‑inflammatory, antioxidative and antiapoptotic effects by inhibited the TNF signal pathway. YSJZD warrants further investigation as a clinical empirical prescription.

View Figures

View References

1	Zhang Q, Qi J, Luo Q, Wu M, Zhang L, Qin L and Nie X: Yishen Xiezhuo formula ameliorates the development of cisplatin-induced acute kidney injury by attenuating renal tubular epithelial cell senescence. Ann Transl Med. 10(1392)2022.PubMed/NCBI View Article : Google Scholar
2	Volarevic V, Djokovic B, Jankovic MG, Harrell CR, Fellabaum C, Djonov V and Arsenijevic N: Molecular mechanisms of cisplatin-induced nephrotoxicity: a balance on the knife edge between renoprotection and tumor toxicity. J Biomed Sci. 26(25)2019.PubMed/NCBI View Article : Google Scholar
3	Oliveira BM, de Almeida LF, Deluque AL, Souza CS, Maciel ALD, Francescato HDC, Costa RS, Giovanini C, de Paula FJA and Coimbra TM: Calcitriol reduces the inflammation, endothelial damage and oxidative stress in AKI caused by cisplatin. Int J Mol Sci. 23(15877)2022.PubMed/NCBI View Article : Google Scholar
4	Lu L, Liu W, Li S, Bai M, Zhou Y, Jiang Z, Jia Z, Huang S, Zhang A and Gong W: Flavonoid derivative DMXAA attenuates cisplatin-induced acute kidney injury independent of STING signaling. Clin Sci (Lond). 137:435–452. 2023.PubMed/NCBI View Article : Google Scholar
5	McSweeney KR, Gadanec LK, Qaradakhi T, Ali BA, Zulli A and Apostolopoulos V: Mechanisms of cisplatin-induced acute kidney injury: Pathological mechanisms, pharmacological interventions and genetic mitigations. Cancers (Basel). 13(1572)2021.PubMed/NCBI View Article : Google Scholar
6	Holditch SJ, Brown CN, Lombardi AM, Nguyen KN and Edelstein CL: Recent advances in models, mechanisms, biomarkers and interventions in cisplatin-induced acute kidney injury. Int J Mol Sci. 20(3011)2019.PubMed/NCBI View Article : Google Scholar
7	Qi L, Luo Q, Zhang Y, Jia F, Zhao Y and Wang F: Advances in toxicological research of the anticancer drug cisplatin. Chem Res Toxicol. 32:1469–1486. 2019.PubMed/NCBI View Article : Google Scholar
8	Fang CY, Lou DY, Zhou LQ, Wang JC, Yang B, He QJ, Wang JJ and Weng QJ: Natural products: Potential treatments for cisplatin-induced nephrotoxicity. Acta Pharmacol Sin. 42:1951–1969. 2021.PubMed/NCBI View Article : Google Scholar
9	Mapuskar KA, Steinbach EJ, Zaher A, Riley DP, Beardsley RA, Keene JL, Holmlund JT, Anderson CM, Zepeda-Orozco D, Buatti JM, et al: Mitochondrial superoxide dismutase in cisplatin-induced kidney injury. Antioxidants (Basel). 10(1329)2021.PubMed/NCBI View Article : Google Scholar
10	Sears SM and Siskind LJ: Potential therapeutic targets for cisplatin-induced kidney injury: Lessons from other models of AKI and Fibrosis. J Am Soc Nephrol. 32:1559–1567. 2021.PubMed/NCBI View Article : Google Scholar
11	Xu YF, Ruan SW, Lin JM and Zhang Z: Yishen Jiangzhuo Granules affect tubulointerstitial fibrosis via a mitochondrion-mediated apoptotic pathway. Chin J Integr Med. 21:928–937. 2015.PubMed/NCBI View Article : Google Scholar
12	Xu SY, Bian RL and Chen X: Experimental methodology of Pharmacology. People's Medical Publishing House, Beijing, 2002.
13	Zhang Y, Chang Y, Han Z, Ma K, Zeng X and Li L: Estrogen protects against renal ischemia-reperfusion injury by regulating Th17/Treg cell immune balance. Dis Markers. 2022(7812099)2022.PubMed/NCBI View Article : Google Scholar
14	Ranasinghe R, Mathai ML and Zulli A: Cisplatin for cancer therapy and overcoming chemoresistance. Heliyon. 8(e10608)2022.PubMed/NCBI View Article : Google Scholar
15	Xu Z, Zhang M, Wang W, Zhou S, Yu M, Qiu X, Jiang S, Wang X, Tang C, Li S, et al: Dihydromyricetin attenuates cisplatin-induced acute kidney injury by reducing oxidative stress, inflammation and ferroptosis. Toxicol Appl Pharmacol. 473(116595)2023.PubMed/NCBI View Article : Google Scholar
16	Chou YN, Lee MM, Deng JS, Jiang WP, Lin JG and Huang GJ: Water extract from brown strain of flammulina velutipes alleviates cisplatin-induced acute kidney injury by attenuating oxidative stress, inflammation, and autophagy via PI3K/AKT pathway regulation. Int J Mol Sci. 24(9448)2023.PubMed/NCBI View Article : Google Scholar
17	Linkermann A, Bräsen JH, Darding M, Jin MK, Sanz AB, Heller JO, De Zen F, Weinlich R, Ortiz A, Walczak H, et al: Two independent pathways of regulated necrosis mediate ischemia-reperfusion injury. Proc Natl Acad Sci USA. 110:12024–12029. 2013.PubMed/NCBI View Article : Google Scholar
18	Perse M and Veceric-Haler Z: Cisplatin-induced rodent model of kidney injury: Characteristics and challenges. Biomed Res Int. 2018(1462802)2018.PubMed/NCBI View Article : Google Scholar
19	Ozkok A, Ravichandran K, Wang Q, Ljubanovic D and Edelstein CL: NF-κB transcriptional inhibition ameliorates cisplatin-induced acute kidney injury (AKI). Toxicol Lett. 240:105–113. 2016.PubMed/NCBI View Article : Google Scholar
20	Kim C, Kwak W, Won DH, Kim J, Hwang DB, Kim N, Kang M, Jeon Y, Park YI, Park JW and Yun JW: Loss of Dact2 alleviates cisplatin-induced nephrotoxicity through regulation of the Igfl-MAPK pathway axis. Cell Biol Toxicol. 39:3197–3217. 2023.PubMed/NCBI View Article : Google Scholar
21	Yuan H, Zhao Y, Li S, Qin J and Yu X: Madecassoside ameliorates cisplatin-induced nephrotoxicity by inhibiting activation of the mitogen activated protein kinase pathway. Environ Toxicol. 38:1473–1483. 2023.PubMed/NCBI View Article : Google Scholar
22	Ramesh G and Reeves WB: p38 MAP kinase inhibition ameliorates cisplatin nephrotoxicity in mice. Am J Physiol Renal Physiol. 289:F166–F174. 2005.PubMed/NCBI View Article : Google Scholar
23	Ramesh G and Reeves WB: TNF-alpha mediates chemokine and cytokine expression and renal injury in cisplatin nephrotoxicity. J Clin Invest. 110:835–842. 2002.PubMed/NCBI View Article : Google Scholar
24	Zhang B, Ramesh G, Norbury CC and Reeves WB: Cisplatin-induced nephrotoxicity is mediated by tumor necrosis factor-alpha produced by renal parenchymal cells. Kidney Int. 72:37–44. 2007.PubMed/NCBI View Article : Google Scholar
25	Ramesh G, Kimball SR, Jefferson LS and Reeves WB: Endotoxin and cisplatin synergistically stimulate TNF-alpha production by renal epithelial cells. Am J Physiol Renal Physiol. 292:F812–F819. 2007.PubMed/NCBI View Article : Google Scholar
26	Pan Y, Zhang Y, Li J, Zhang Z, He Y, Zhao Q, Yang H and Zhou P: A proteoglycan isolated from Ganoderma lucidum attenuates diabetic kidney disease by inhibiting oxidative stress-induced renal fibrosis both in vitro and in vivo. J Ethnopharmacol. 310(116405)2023.PubMed/NCBI View Article : Google Scholar
27	Lu XH, Zhang J and Xiong Q: Suppressive effect erythropoietin on oxidative stress by targeting AMPK/Nox4/ROS pathway in renal ischemia reperfusion injury. Transpl Immunol. 72(101537)2022.PubMed/NCBI View Article : Google Scholar
28	Ma Q, Xu Y, Tang L, Yang X, Chen Z, Wei Y, Shao X, Shao X, Xin Z, Cai B, et al: Astragalus polysaccharide attenuates cisplatin-induced acute kidney injury by suppressing oxidative damage and mitochondrial dysfunction. Biomed Res Int. 2020(2851349)2020.PubMed/NCBI View Article : Google Scholar
29	Yang L, Wang B, Guo F, Huang R, Liang Y, Li L, Tao S, Yin T, Fu P and Ma L: FFAR4 improves the senescence of tubular epithelial cells by AMPK/SirT3 signaling in acute kidney injury. Signal Transduct Target Ther. 7(384)2022.PubMed/NCBI View Article : Google Scholar
30	Huang Z, Li Q, Yuan Y, Zhang C, Wu L, Liu X, Cao W, Guo H, Duan S, Xu X, et al: Renalase attenuates mitochondrial fission in cisplatin-induced acute kidney injury via modulating sirtuin-3. Life Sci. 222:78–87. 2019.PubMed/NCBI View Article : Google Scholar
31	Li Y, Ye Z, Lai W, Rao J, Huang W, Zhang X, Yao Z and Lou T: Activation of sirtuin 3 by silybin attenuates mitochondrial dysfunction in cisplatin-induced acute kidney injury. Front Pharmacol. 8(178)2017.PubMed/NCBI View Article : Google Scholar
32	Morigi M, Perico L, Rota C, Longaretti L, Conti S, Rottoli D, Novelli R, Remuzzi G and Benigni A: Sirtuin 3-dependent mitochondrial dynamic improvements protect against acute kidney injury. J Clin Invest. 125:715–726. 2015.PubMed/NCBI View Article : Google Scholar
33	Zi Y, Wang X, Zi Y, Yu H, Lan Y, Fan Y, Ren C, Liao K and Chen H: Cigarette smoke induces the ROS accumulation and iNOS activation through deactivation of Nrf-2/SIRT3 axis to mediate the human bronchial epithelium ferroptosis. Free Radic Biol Med. 200:73–86. 2023.PubMed/NCBI View Article : Google Scholar
34	Wen L, Wei Q, Livingston MJ, Dong G, Li S, Hu X, Li Y, Huo Y and Dong Z: PFKFB3 mediates tubular cell death in cisplatin nephrotoxicity by activating CDK4. Transl Res. 253:31–40. 2023.PubMed/NCBI View Article : Google Scholar
35	Lee D, Yamabe N, Lee H, Lim Lee H, Kim DW, Wook Lee J and Sung Kang K: Necrostatins regulate apoptosis, necroptosis, and inflammation in cisplatin-induced nephrotoxicity in LLC-PK1 cells. Bioorg Med Chem Lett. 48(128256)2021.PubMed/NCBI View Article : Google Scholar
36	Oh GS, Kim HJ, Shen A, Lee SB, Khadka D, Pandit A and So HS: Cisplatin-induced kidney dysfunction and perspectives on improving treatment strategies. Electrolyte Blood Press. 12:55–65. 2014.PubMed/NCBI View Article : Google Scholar